Today, no products exist to comprehensively fight pathogens. Only vaccines offer any protection; however, they are not readily affordable worldwide and tend to be effective against a narrow range of pathogenic viruses.
Antibiotics each target a limited number of pathogenic bacteria, but their efficacy is diminishing, and no new classes of antibiotics have been brought to market for over 40 years.
Products to counter fungals are limited in availability and are not cures.
Developing a new and innovative product to effectively fight pathogens
Qures Group Ltd (QURES) is a healthcare pharmaceutical company established in 2016. Its purpose is to bring to market a product that is affordable worldwide and fights pathogens in and on the human body.
Research has shown in-vitro efficacy against pathogenic bacteria, including resistant species, Type A and Type B viruses, non-pathogenic Coronaviruses, and COVID-19, as well as against fungal pathogens.
QURES’ proprietary approach recognises the ability of the human innate defence system to fight and kill all pathogens. Having created delivery systems for products that mimic the innate immune system is a substantial advantage for the Company’s ambitions and success.
Platform technology delivers efficient antimicrobial materials
QURES has been established to develop and commercialise a platform technology in affordable, orally bioavailable preparations capable of delivering efficacious concentrations of antimicrobial materials systemically (rapid absorption) with rapid efficacy and competence to destroy all kinds of pathogens – be they bacterial, viral or fungal.
Yet, at the same time, it is safe for use in humans, animals, and agriculture, and it does not damage naturally occurring materials such as human cells, commensal bacteria, or DNA.
We have fully developed two products from the platform so far, which are ready for human safety clinical trials and hope to be commercially available by 2026.
In addition to infections and diseases, we can provide answers to two major concerns for humans—the microbiome and mental concerns—both of which have increased to pandemic proportions worldwide.
About Richard Stead, CEO
After graduating with a degree in Chemistry, Richard Stead spent most of the next 35 years working in the food supplement and additive industries, starting and selling several companies in this arena.
Nature’s competence opened his eyes, and he was amazed that humans preferred to believe we could do better than nature. He was horrified by the extent of so many materials that were damaging to humans and food, such as chlorine.
Seeking safer and better alternatives to chlorine, he followed his principal belief: NATURE HAS THE ANSWER, CHEMISTRY IS THE KEY.
He finally settled on a significant chemistry based around the human innate immune system, which has been his passion for the last ten years and is the basis of his article this month.
